4.8 Article

In vivo discovery of immunotherapy targets in the tumour microenvironment

Journal

NATURE
Volume 506, Issue 7486, Pages 52-+

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nature12988

Keywords

-

Funding

  1. National Institutes of Health [1R01CA173750]
  2. Melanoma Research Alliance
  3. DF/HCC-MIT Bridge Project
  4. Lustgarten Foundation
  5. Novartis Institutes of Biomedical Research
  6. Koch Institute from the National Cancer Institute [P30-CA14051]
  7. American Cancer Society
  8. Terri Brodeur Breast Cancer Foundation
  9. NIH [AI07386]

Ask authors/readers for more resources

Recent clinical trials showed that targeting of inhibitory receptors on T cells induces durable responses in a subset of cancer patients, despite advanced disease. However, the regulatory switches controlling T-cell function in immunosuppressive tumours are not well understood. Here we show that such inhibitory mechanisms can be systematically discovered in the tumour microenvironment. We devised an in vivo pooled short hairpin RNA (shRNA) screen in which shRNAs targeting negative regulators became highly enriched in murine tumours by releasing a block on T-cell proliferation upon tumour antigen recognition. Such shRNAs were identified by deep sequencing of the shRNA cassette from T cells infiltrating tumour or control tissues. One of the target genes was Ppp2r2d, a regulatory subunit of the PP2A phosphatase family. In tumours, Ppp2r2d knockdown inhibited T-cell apoptosis and enhanced T-cell proliferation as well as cytokine production. Key regulators of immune function can therefore be discovered in relevant tissue microenvironments.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available